000			02422na a2200325 4500
999			_c6096 _d6096
003			PC6096
005			20191030141818.0
008			130622s2013 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aAndrés Belmonte, Amado _91321 _eNefrología
245	0	0	_aHigh incidence of delayed graft function in HIV-infected kidney transplant recipients. _h[artículo]
260			_bTransplant International, _c2013
300			_a26(9):893-902.
500			_aFormato Vancouver: Mazuecos A, Fernández A, Zarraga S, Andrés A, Rodríguez-Benot A, Jiménez C et al. High incidence of delayed graft function in HIV-infected kidney transplant recipients. Transpl Int. 2013 Sep;26(9):893-902.
501			_aPMID: 23841527
504			_aContiene 31 referencias
520			_aKidney transplantation (KT) outcomes in human immunodeficiency virus (HIV)-infected recipients are under continuous research. High incidence of early post-transplant complications such as acute rejection has been observed. A multicenter study including HIV-infected patients who underwent KT in Spain, from 2001 to 2011, was performed. The study population included 108 recipients, 36 HIV-infected, and 72 matched HIV-negative KT recipients. HIV-infected recipients developed more delayed graft function (DGF) (52% vs. 21%, P < 0.001). One- and 3-year graft survival was 91.6% and 86.2% in HIV-infected patients, and 97.1% and 94.7% in HIV-negative patients (P = 0.052). In two-variate Cox analysis, HIV infection was not a predictor of graft loss after adjusting for time on dialysis, acute rejection, and DGF. Multivariate analysis for DGF revealed HIV-positive status as independent risk factor. We analyzed the evolution of immunosuppressive and antiretroviral therapy (ART). In HIV-infected patients tacrolimus trough levels were very high in the first week and significantly lower in the second week post-transplant (P = 0.042). Post-transplant ART was significantly changed: protease inhibitors use decreased (P = 0.034) and integrase inhibitor use increased (P < 0.001). DGF is another frequent early complication in HIV-infected recipients that can affect graft survival. Strategies to prevent DGF and antiretroviral regimes with less drug interactions could improve outcomes.
710			_986 _aServicio de Nefrología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/6/pc6096.pdf _ySolicitar documento
942			_n0 _2ddc _cART